Long-Term Use Of Temozolomide As Safe And Effective Therapy For An Aggressive Corticotroph Adenoma In A Very Old Patient

JOURNAL OF THE ENDOCRINE SOCIETY(2021)

引用 4|浏览3
暂无评分
摘要
Background: Temozolomide (TMZ) is safe and effective in the treatment of aggressive pituitary adenomas (PAs). However, the optimal duration of TMZ therapy is still unknown. Moreover, data about administration ofTMZ in elderly (>= 65 years) people to treat aggressive PAs are scarce. We report the case of the oldest female patient undergoing the longest TMZ protocol described so far to treat an aggressive, initially silent corticotroph PA.Case report: The patient initially underwent partial surgical removal of the PA. Subsequent treatment with cabergoline was applied, but it was unsuccessful in controlling the growth of the residual tumor. Pasireotide and external radiation also showed to be ineffective; therefore, treatment withTMZ was started at the standard dose of 200 mg/ m 2 /day for 5 days every 4 weeks for a total of 47 cycles. At the time of treatment's beginning, the patient was 83 years old. Radiological follow-up documented a progressive, remarkable reduction of the adenoma and the last imaging, after 39 cycles of TMZ, showed an intrasellar lesion with large areas of cystic degeneration.The patient also developed adrenal deficiency managed with glucocorticoid replacement. No major side effects were observed throughout the treatment, with exception of nausea, well controlled with anti-emetic medication. TMZ therapy was discontinued after 47 cycles; hormonal and imaging follow-up investigations documented sustained functional and dimensional response.Conclusions: Our case supports the long-term use of TMZ, confirming its safety and efficacy also for elderly patients.
更多
查看译文
关键词
temozolomide, aggressive pituitary adenoma, old age, long-term treatment, case report
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要